Changes Of Serum Platelet-derived Growth Factor -Bb In Patients Undergoing Surgery With Thyroid Papillary Carcinoma Before And After ¹³¹I Treatment

Objective:Platelet-derived growth factor-BB is a peptide Kind produced by a variety of cell growth factors, with the promotion of various malignant tumors angiogenesis, lymphangiogenesis and anti-apoptotic function.Some studies have indicated that compared to the normal thyroid the PDGF-B chain is significantly over expressed in patients with papillary thyroid carcinoma , that is, serum PDGF-B plays an important role in the occurrence, progression and metastasis of PTC[1].This experiment is to compare the changes of serum PDGF-BB levels in papillary thyroid cancer patients who underwent 131Iodion treatment and compared the differences of serum PDGF-BB levels before 131Iodion treatment between different groups(metastasis group and no metastasis group), and analysis of the relationship between serum PDGF-BB levels and different clinical pathology after 131Iodion treatment,to identify the clinical value of serum PDGF-BB levels and the effect assessment of 131Iodion treatment of PTC patient.Methods:In this experiment, 104 cases with papillary thyroid carcinoma patients as research subjects,who were diagnosed by pathological diagnosis, Posttreatment whole body scan(Rx-WBS) was carried from 5to7 days after 131Iodion treatment ,and all patients were divided into a metastasis group and a no metastasis group according to the resultes Rx-WBS.Using double antibody sandwich enzyme-linked immunosorbent assay and the statistical methods to compare the changes of serum PDGF-BB levels before and after 131Iodion treatment, and to analyze their correlation with different clinical pathological characteristics.Results:1.The serum PDGF-BB level of PTC patients after 131Iodine treatment( the first month after 131Iodion treatment: 403.89 ± 129.81 ng/L,the third month after 131Iodion treatment:401.57 ± 430.68 ng/L,the sixth month after 131Iodion treatment:390.04± 118.46 ng/L) was significantly lower than that before 131Iodion treatment (443.15 ± 127.14 ng/L).there was significant difference between these two groups(P < 0.05).2.In the first month after 131Iodion treatment,the serum PDGF-BB level of metastasis group was 464.81 ± 142.35 ng/L,and the serum PDGF-BB level of no metastasis group was 403.47 ± 108.21 ng/L;In the third month after 131Iodion treatment,the serum PDGF-BB level of metastasis group was 472.27 ± 142.91 ng/L,and the serum PDGF-BB level of no metastasis group was 397.56 ± 106.78 ng/L;In the sixth month after 131Iodion treatment,the serum PDGF-BB level of metastasis group was 472.26 ± 142.97 ng/L,and the serum PDGF-BB level of no metastasis group was 392.79 ± 106.32 ng/L.In the three groups,compared with metastasis group and no metastasis group,the differences were statistically significant (P < 0.05).3.According to age, sex, tumor size, lymph node metastasis, T stage, capsule invasion, TNM staging and other clinical pathological characteristics were compared. Serum PDGF-BB levels were correlated with lymph node metastasis and TNM stage (P<0.05,r=0.742,0.639), and were independent of age, sex, tumor size, T stage, and capsule infiltration (P>0.05,r=0.268,0.122,0.351,0.236,0.107).Conclusions:1.It is meaning for the serum PDGF-BB level of PTC patients to assess the clinical effect of131 Iodion treatment.2.he serum PDGF-BB level is related to the progression, invasion and metastasis of papillary thyroid carcinoma. The detection of serum PDGF-BB level is helpful for the early diagnosis, treatment and prognosis of papillary thyroid carcinoma.